Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -0.77%87 ROA % is 4.41% as of Mar. 2026, which is 73% below its 10-year median of 16.56. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Blau Farmaceutica ranks better than 71.2% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Blau Farmaceutica's annualizedNet Income for the quarter that ended in Mar. 2026 was R$159 Mil.
Blau Farmaceutica's average Total Assets over the quarter that ended in Mar. 2026 was R$3,604 Mil. Therefore, Blau Farmaceutica's annualized ROA % for the quarter that ended in Mar. 2026 was 4.41%.
The historical rank and industry rank for Blau Farmaceutica's ROA % or its related term are showing as below:
BSP:BLAU3'
s ROA % Range Over the Past 10 Years
Min: 6.72 Med: 16.56 Max: 30.26
Current: 6.87
During the past 10 years, Blau Farmaceutica's highest ROA % was 30.26%. The lowest was 6.72%. And the median was 16.56%.
BSP:BLAU3's ROA % is ranked better than 71.2% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs BSP:BLAU3: 6.87
Blau Farmaceutica (BSP:BLAU3) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Blau Farmaceutica ROA % Related Terms
Blau Farmaceutica ROA % Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's ROA % distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Blau Farmaceutica (BSP:BLAU3) has a ROA % of 4.41% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Blau Farmaceutica and its competitors. This is 73% below median its historical median of 16.56. Over the past decade, Blau Farmaceutica's ROA % has ranged from 6.72 to 30.26. According to the industry distribution chart, Blau Farmaceutica ranks #290 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 28.8%.
Is Blau Farmaceutica's ROA % too high?
Blau Farmaceutica's current ROA % of 4.41% is 73% below median its 10-year median of 16.56. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 30.26. The Drug Manufacturers industry median ROA % is 2.74. Blau Farmaceutica's value of 4.41% is 60.9% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #290 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #290 out of 1007 companies for ROA %. This puts Blau Farmaceutica in the upper half of its industry. The industry median ROA % is 2.74. Blau Farmaceutica's value of 4.41% is 60.9% above this benchmark. Historically, Blau Farmaceutica's own ROA % has ranged from 6.72 to 30.26 over the past decade. While the company's 10-year median is 16.56 vs. the industry median of 2.74, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current ROA % of 4.41% is 60.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current ROA % is 4.41%, which is 73% below median its own 10-year median of 16.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.17, compared to a current price of R$8.98 — trading 19.6% below its estimated fair value. The current ROA % is 4.41%, which is 73% below median its 10-year median of 16.56 and 60.9% above the Drug Manufacturers industry median of 2.74. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current ROA % is 4.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.98 is trading 19.6% below its estimated GF Value™ of R$11.17.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
ROA %: 4.41% (73% below median its 10-year median of 16.56)
GF Value™: R$11.17 vs. price of R$8.98 (19.6% below fair value)
Industry Position: 60.9% above the Drug Manufacturers median (#290 of 1007)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
